CU23389B6 - CITOPROTECTOR PHARMACEUTICAL COMBINATION, USEFUL IN THE PREVENTION AND TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME - Google Patents
CITOPROTECTOR PHARMACEUTICAL COMBINATION, USEFUL IN THE PREVENTION AND TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROMEInfo
- Publication number
- CU23389B6 CU23389B6 CU20050284A CU20050284A CU23389B6 CU 23389 B6 CU23389 B6 CU 23389B6 CU 20050284 A CU20050284 A CU 20050284A CU 20050284 A CU20050284 A CU 20050284A CU 23389 B6 CU23389 B6 CU 23389B6
- Authority
- CU
- Cuba
- Prior art keywords
- inflammatory response
- pharmacological combination
- inflammatory
- citoprotector
- prevention
- Prior art date
Links
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 4
- 230000028709 inflammatory response Effects 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000001120 cytoprotective effect Effects 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 101000779583 Limulus polyphemus Anti-lipopolysaccharide factor Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000007124 immune defense Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000003990 molecular pathway Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención trata de una combinación farmacológica entre una proteína con propiedades citoprotectoras y un péptido inmunomodulador. El Péptido de la combinación farmacológica es el LALF 31-52 lineal, que incrementa los mecanismos de defensa inmunológica, sin inducir una respuesta inflamatoria exacerbada. La proteína de la combinación farmacológica es el Factor de Crecimiento Epidérmico que posee un efecto citoprotector y activa la transducción de senales de genes de sobrevida celular. La combinación farmacológica de la presente invención confiere resistencia a las células sistémicas e inmunocomponentes, para tolerar el dano inducido por las citoquinas inflamatorias y por endotoxinas bacterianas, sin activar vías moleculares de apoptosis. Además, atenúa los eventos inflamatorios de la primera etapa de la sepsis y de la respuesta inflamatoria ante traumatismos estériles, permitiendo la defensa del organismo contra la invasión de patógenos o contra los mediadores de la inflamación, sin que la respuesta inflamatoria sea deletérea a su integridad.The present invention relates to a pharmacological combination between a protein with cytoprotective properties and an immunomodulatory peptide. The Peptide of the pharmacological combination is the linear LALF 31-52, which increases the mechanisms of immune defense, without inducing an exacerbated inflammatory response. The protein of the pharmacological combination is the Epidermal Growth Factor that has a cytoprotective effect and activates the signal transduction of cell survival genes. The pharmacological combination of the present invention confers resistance to systemic and immunocomponent cells, to tolerate damage induced by inflammatory cytokines and bacterial endotoxins, without activating molecular pathways of apoptosis. In addition, it attenuates the inflammatory events of the first stage of sepsis and the inflammatory response to sterile trauma, allowing the organism to defend against invasion of pathogens or against mediators of inflammation, without the inflammatory response being deleterious to its integrity. .
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050284A CU23389B6 (en) | 2005-12-29 | 2005-12-29 | CITOPROTECTOR PHARMACEUTICAL COMBINATION, USEFUL IN THE PREVENTION AND TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME |
| PCT/CU2006/000017 WO2007073703A1 (en) | 2005-12-29 | 2006-12-28 | Cytoprotective pharmaceutical combination which can be used in the prevention and treatment of systemic inflammatory response syndrome |
| ARP060105841A AR058875A1 (en) | 2005-12-29 | 2006-12-28 | PHARMACEUTICAL CYTROTECTING COMBINATION USEFUL IN THE PREVENTION AND TREATMENT OF THE SYSTROME SYSTEM OF INFLAMMATORY RESPONSE |
| CA002635342A CA2635342A1 (en) | 2005-12-29 | 2006-12-28 | Cytoprotective pharmaceutical combination which can be used in the prevention and treatment of systemic inflammatory response syndrome |
| BRPI0620817A BRPI0620817A2 (en) | 2005-12-29 | 2006-12-28 | pharmaceutical combination for the prevention and treatment of inflammatory response syndrome triggered by septic or sterile insults |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050284A CU23389B6 (en) | 2005-12-29 | 2005-12-29 | CITOPROTECTOR PHARMACEUTICAL COMBINATION, USEFUL IN THE PREVENTION AND TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23389B6 true CU23389B6 (en) | 2009-07-16 |
Family
ID=37773591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20050284A CU23389B6 (en) | 2005-12-29 | 2005-12-29 | CITOPROTECTOR PHARMACEUTICAL COMBINATION, USEFUL IN THE PREVENTION AND TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR058875A1 (en) |
| BR (1) | BRPI0620817A2 (en) |
| CA (1) | CA2635342A1 (en) |
| CU (1) | CU23389B6 (en) |
| WO (1) | WO2007073703A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5590004B2 (en) * | 2011-10-24 | 2014-09-17 | 新日鐵住金株式会社 | Rectification stand for solar power generation panel |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22700A1 (en) * | 1997-09-29 | 2001-07-31 | Ct Ingenieria Genetica Biotech | ANTI-VIRAL PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-LPS PROTEIN PEPTIDE FROM LIMULUS FACTOR AND ITS USE |
| CU23157A1 (en) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TISSULAR DANE DUE TO LACK OF BLOOD IRRIGATION ARTERIAL |
-
2005
- 2005-12-29 CU CU20050284A patent/CU23389B6/en unknown
-
2006
- 2006-12-28 AR ARP060105841A patent/AR058875A1/en not_active Application Discontinuation
- 2006-12-28 WO PCT/CU2006/000017 patent/WO2007073703A1/en active Application Filing
- 2006-12-28 CA CA002635342A patent/CA2635342A1/en not_active Abandoned
- 2006-12-28 BR BRPI0620817A patent/BRPI0620817A2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007073703A1 (en) | 2007-07-05 |
| CA2635342A1 (en) | 2007-07-05 |
| AR058875A1 (en) | 2008-02-27 |
| BRPI0620817A2 (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121658T1 (en) | PEPTIDES AND THEIR USE | |
| AR062281A1 (en) | LAMINATED IN THE FORM OF ELASTIC TONGUE AND WITH FORM | |
| GT201200125A (en) | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME | |
| BR112012032695A2 (en) | Double cell plastic cover for architectural openings. | |
| GT201100006A (en) | SALCILATOS ACETYLATED WITH FATTY ACIDS AND THEIR USES | |
| CO6290718A2 (en) | TWO-BASED SKATEBOARD WITH A SPRING DAMAGE SYSTEM | |
| WO2009051717A3 (en) | Human factor ix variants with an extended half life | |
| DE502008001664D1 (en) | Solar module arrangement and roof arrangement | |
| WO2010144344A3 (en) | Melanocortin receptor-specific peptides | |
| EP2348039A3 (en) | Cyclic antimicrobial peptides | |
| CR10938A (en) | COMBINED EFFECTS OF TOPIRAMATE AND ONDANSETRON ON THE CONSUMPTION OF ALCOHOL | |
| ES2688030T3 (en) | Permeable cell peptides inhibitors of the JNK signal transduction pathway for use in the treatment of inflammatory eye diseases | |
| ECSP10010196A (en) | ACID DERIVATIVES OF ACID 6,7-DIHIDRO-5H-IMIDAZO [1,2-A] IMIDAZOL-3-CARBOXYL | |
| HK1142828A1 (en) | Hydrolysable polymeric fmoc-linker | |
| IL313142A (en) | Multi-stage adsorber device and uses thereof for chilling and/or atmospheric water harvesting | |
| CU23389B6 (en) | CITOPROTECTOR PHARMACEUTICAL COMBINATION, USEFUL IN THE PREVENTION AND TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | |
| AR093647A1 (en) | MICROCAPE COMPONENT FOR FILMS WITH GAS BARRIER / HUMIDITY IMPROVED BY CONTROL OF THE CRYSTAL LAMINAR ORIENTATION | |
| BR112017011280A2 (en) | laminated from a sheet of thick polymeric material and a sheet of thin glass | |
| ITRM20040349A1 (en) | ANTIBACTERIAL PEPTIDES AND THEIR ANALOGUES. | |
| WO2009068682A3 (en) | Phenyl-oxetanyl-derivatives | |
| WO2010020677A3 (en) | Protein c variants | |
| CO2020016749A2 (en) | Novel protein with anti-inflammatory properties | |
| ATE517297T1 (en) | SUBCONSTRUCTION FOR FIELD SOLAR SYSTEMS | |
| Thong et al. | Global warming and its dermatologic implications. | |
| GT200800089A (en) | PROCEDURE FOR THE PREPARATION OF THE CELL PHONE INHIBITOR -779 CRYSTAL AND PURIFIED |